Mylan Puts Its Troubles in the Past, at a Price of $465 MillionBy
Settlement ‘gets the U.S. government out of Mylan’s hair’
Shares gain on Monday morning following Friday deal with U.S.
The worst appears to be over for Mylan NV and its EpiPen controversy. It took a $465 million settlement with the U.S. Justice Department and a grilling from Congress for its chief executive officer to get there.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Smartphones Are Killing Americans, But Nobody’s Counting
- Why a Pub in the Middle of Nowhere Was Named the World’s Best Restaurant
- Ford to Take $267 Million Hit From Recall of F-Series Trucks
- Facebook and Google Helped Anti-Refugee Campaign in Swing States
- Gulf Coast Oil Spill May Be Largest Since 2010 BP Disaster